Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops
PLoS Neglected Tropical Diseases, Volume 4, No. 11, Article e895, Year 2010
Notification
URL copied to clipboard!
Description
Background: Following an epidemiological study carried out in 2006 showing a high prevalence of blinding trachoma in the Far North Region of Cameroon, a trachoma elimination programme using the SAFE strategy was initiated: three yearly trachoma mass treatments were to be performed. Methodology/Principal Findings: The entire district population (120,000 persons) was treated with azithromycin 1.5% eye drops in February 2008 and January 2009. To assess the effect of treatment on the prevalence of active trachoma, three epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the first treatment, the second just prior to the 2nd treatment and the third one, one year later. The prevalence of active forms of trachoma (TF + TI) dropped from 31.5% (95%CI 26.4-37.5) before treatment to 6.3% (95%CI 4.1-9.6) one year after first treatment; a reduction of nearly 80%. One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%. Furthermore, there were no more TI cases (only TF). There was no report of serious or systemic side effects. Tolerance was excellent. Conclusions/Significance: Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective. © 2010 Amza et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC2990706/bin/pntd.0000895.s001.doc
Authors & Co-Authors
Amza, Abdou
Niger
Faculté Des Sciences de la Santé
Goldschmidt, Pablo L.
France, Paris
Centre Hospitalier National D‘ophtalmologie Des Quinze-vingts
Einterz, Ellen M.
Cameroon
Kolofata District Health Service
Huguet, Pierre
France, Clermont-ferrand
Laboratoires Théa
Olmiere, Celine
France, Clermont-ferrand
Laboratoires Théa
Bensaïd, Philippe
Unknown Affiliation
Bella-Assumpta, Lucienne
Cameroon, Yaounde
Ministry of Health
Statistics
Citations: 20
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1371/journal.pntd.0000895
Research Areas
Health System And Policy
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Cameroon